Global Retirement Partners LLC Raises Stake in IDEXX Laboratories, Inc. $IDXX

Global Retirement Partners LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 226.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,834 shares of the company’s stock after buying an additional 1,273 shares during the quarter. Global Retirement Partners LLC’s holdings in IDEXX Laboratories were worth $1,241,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Beacon Investment Advisory Services Inc. boosted its holdings in shares of IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after buying an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd boosted its holdings in shares of IDEXX Laboratories by 14.5% in the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after buying an additional 4,909 shares during the last quarter. Finally, Procyon Advisors LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $1,966,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares in the company, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 27,777 shares of company stock worth $18,235,113. Company insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Barclays lowered their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, BTIG Research lowered their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $559.37 on Monday. IDEXX Laboratories, Inc. has a 52-week low of $496.61 and a 52-week high of $769.98. The stock’s 50-day simple moving average is $566.51 and its 200 day simple moving average is $642.13. The stock has a market capitalization of $44.12 billion, a P/E ratio of 41.19, a P/E/G ratio of 3.25 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business posted $2.91 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.